Annual Gross Margin
92.50%
-2.55%-2.68%
December 31, 2023
Summary
- As of February 7, 2025, LCTX annual gross profit margin is 92.50%, with the most recent change of -2.55% (-2.68%) on December 31, 2023.
- During the last 3 years, LCTX annual gross margin has risen by +42.31% (+84.30%).
- LCTX annual gross margin is now -62.06% below its all-time high of 243.81%, reached on December 31, 2000.
Performance
LCTX Gross Margin Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Gross Margin
98.99%
+2.11%+2.18%
September 30, 2024
Summary
- As of February 7, 2025, LCTX quarterly gross profit margin is 98.99%, with the most recent change of +2.11% (+2.18%) on September 30, 2024.
- Over the past year, LCTX quarterly gross margin has increased by +12.55% (+14.52%).
- LCTX quarterly gross margin is now -76.49% below its all-time high of 421.05%, reached on March 31, 2000.
Performance
LCTX Quarterly Gross Margin Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Gross Margin Formula
Gross Margin = Gross Profit
Revenue ✕ 100%
Revenue ✕ 100%
LCTX Gross Margin Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -2.7% | +14.5% |
| 3 y3 years | +84.3% | +7.4% |
| 5 y5 years | +17.6% | +60.3% |
LCTX Gross Margin Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -2.7% | +45.9% | at high | +25.7% |
| 5 y | 5-year | -2.7% | +84.3% | at high | +308.4% |
| alltime | all time | -62.1% | +118.5% | -76.5% | +199.0% |
Lineage Cell Therapeutics Gross Margin History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | 98.99%(+2.2%) |
| Jun 2024 | - | 96.88%(+3.9%) |
| Mar 2024 | - | 93.21%(+6.2%) |
| Dec 2023 | 92.50%(-2.7%) | 87.74%(+1.5%) |
| Sep 2023 | - | 86.44%(-10.0%) |
| Jun 2023 | - | 96.06%(+1.1%) |
| Mar 2023 | - | 95.01%(+0.4%) |
| Dec 2022 | 95.05%(+49.9%) | 94.67%(+2.7%) |
| Sep 2022 | - | 92.16%(-3.3%) |
| Jun 2022 | - | 95.28%(-1.4%) |
| Mar 2022 | - | 96.64%(+22.7%) |
| Dec 2021 | 63.40%(+26.3%) | 78.75%(+42.5%) |
| Sep 2021 | - | 55.27%(-22.9%) |
| Jun 2021 | - | 71.66%(+16.0%) |
| Mar 2021 | - | 61.77%(+97.2%) |
| Dec 2020 | 50.19%(-30.4%) | 31.33%(-55.4%) |
| Sep 2020 | - | 70.18%(+189.5%) |
| Jun 2020 | - | 24.24%(-44.1%) |
| Mar 2020 | - | 43.37%(-49.1%) |
| Dec 2019 | 72.12%(-8.3%) | 85.22%(+79.5%) |
| Sep 2019 | - | 47.47%(-17.0%) |
| Jun 2019 | - | 57.20%(-7.8%) |
| Mar 2019 | - | 62.01%(-10.9%) |
| Dec 2018 | 78.67%(-13.2%) | 69.59%(-19.8%) |
| Sep 2018 | - | 86.74%(+5.1%) |
| Jun 2018 | - | 82.51%(+16.3%) |
| Mar 2018 | - | 70.93%(-21.6%) |
| Dec 2017 | 90.63%(+7.8%) | 90.51%(+2.0%) |
| Sep 2017 | - | 88.77%(-10.1%) |
| Jun 2017 | - | 98.69%(+16.2%) |
| Mar 2017 | - | 84.96%(-17.2%) |
| Dec 2016 | 84.10% | 102.64%(+20.6%) |
| Sep 2016 | - | 85.13%(+4.8%) |
| Jun 2016 | - | 81.23%(+31.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2016 | - | 61.60%(-15.6%) |
| Dec 2015 | 56.31%(-1.2%) | 72.97%(+50.2%) |
| Sep 2015 | - | 48.57%(-11.0%) |
| Jun 2015 | - | 54.55%(+2.4%) |
| Mar 2015 | - | 53.27%(+6.8%) |
| Dec 2014 | 57.01%(-21.1%) | 49.89%(-13.2%) |
| Sep 2014 | - | 57.46%(+24.8%) |
| Jun 2014 | - | 46.04%(-37.0%) |
| Mar 2014 | - | 73.13%(-11.2%) |
| Dec 2013 | 72.28%(-2.8%) | 82.33%(+31.4%) |
| Sep 2013 | - | 62.67%(-4.2%) |
| Jun 2013 | - | 65.42%(+0.4%) |
| Mar 2013 | - | 65.13%(-5.7%) |
| Dec 2012 | 74.35%(-21.9%) | 69.05%(-1.1%) |
| Sep 2012 | - | 69.79%(-9.1%) |
| Jun 2012 | - | 76.76%(-16.5%) |
| Mar 2012 | - | 91.94%(-9.7%) |
| Dec 2011 | 95.24%(-2.8%) | 101.85%(+3.5%) |
| Sep 2011 | - | 98.41%(+1.6%) |
| Jun 2011 | - | 96.82%(-6.1%) |
| Dec 2010 | 97.98%(-59.8%) | 103.11%(-24.6%) |
| Dec 2000 | 243.81%(+130.6%) | 136.76%(-60.9%) |
| Jun 2000 | - | 350.00%(-16.9%) |
| Mar 2000 | - | 421.05%(-521.0%) |
| Dec 1999 | 105.73%(-121.1%) | - |
| Sep 1995 | - | -100.00%(0.0%) |
| Dec 1993 | - | -100.00%(0.0%) |
| Sep 1993 | - | -100.00%(<-9900.0%) |
| Jun 1993 | -500.00%(+66.7%) | - |
| Mar 1993 | - | 0.00%(-100.0%) |
| Dec 1992 | - | -100.00%(<-9900.0%) |
| Sep 1992 | - | 0.00%(0.0%) |
| Jun 1992 | -300.00% | - |
| Mar 1992 | - | 0.00% |
FAQ
- What is Lineage Cell Therapeutics annual gross profit margin?
- What is the all time high annual gross margin for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual gross margin year-on-year change?
- What is Lineage Cell Therapeutics quarterly gross profit margin?
- What is the all time high quarterly gross margin for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly gross margin year-on-year change?
What is Lineage Cell Therapeutics annual gross profit margin?
The current annual gross margin of LCTX is 92.50%
What is the all time high annual gross margin for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual gross profit margin is 243.81%
What is Lineage Cell Therapeutics annual gross margin year-on-year change?
Over the past year, LCTX annual gross profit margin has changed by -2.55% (-2.68%)
What is Lineage Cell Therapeutics quarterly gross profit margin?
The current quarterly gross margin of LCTX is 98.99%
What is the all time high quarterly gross margin for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly gross profit margin is 421.05%
What is Lineage Cell Therapeutics quarterly gross margin year-on-year change?
Over the past year, LCTX quarterly gross profit margin has changed by +12.55% (+14.52%)